Hutchison China MediTech Limited (NASDAQ:HCM) has received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus target price of $41.00 for the company, according to Zacks. Zacks has also given Hutchison China MediTech an industry rank of 178 out of 265 based on the ratings given to its competitors.
Several research firms have commented on HCM. BidaskClub downgraded shares of Hutchison China MediTech from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Zacks Investment Research cut shares of Hutchison China MediTech from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th.
Large investors have recently added to or reduced their stakes in the stock. Castleark Management LLC acquired a new position in Hutchison China MediTech during the 4th quarter valued at $177,000. Geode Capital Management LLC acquired a new position in Hutchison China MediTech during the 4th quarter valued at $258,000. Mckinley Capital Management LLC Delaware acquired a new position in Hutchison China MediTech during the 4th quarter valued at $1,237,000. Wells Fargo & Company MN acquired a new position in Hutchison China MediTech during the 4th quarter valued at $1,340,000. Finally, Amundi Pioneer Asset Management Inc. acquired a new position in Hutchison China MediTech during the 4th quarter valued at $2,049,000. Hedge funds and other institutional investors own 7.45% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3382406/brokerages-set-41-00-price-target-for-hutchison-china-meditech-limited-hcm.html.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.